Skip to content

Frontlight ResearchEarly access

Trial site

Shanxi Bethune Hospital

Taiyuan, Shanxi 030001, ChinaNot linked to an institution yet

73running trials
20closed trials

The trials here

What the 93 trials at this site are about, from their registry records.

Conditions: Lupus (SLE)11 trials
Lung cancer8 trials
Childhood cancers5 trials
Melanoma5 trials
Asthma4 trials
Gastric and oesophageal cancer4 trials
Multiple myeloma4 trials
Acute lymphoblastic leukaemia3 trials
Chronic kidney disease3 trials
Chronic lymphocytic leukaemia3 trials
Macular degeneration3 trials
Obesity3 trials
and 39 more
Phase: Phase 333 trials
Phase 224 trials
Phase 1/29 trials
Phase 16 trials
Phase 44 trials
Early phase 11 trial
Phase 2/31 trial
Status: Recruiting30 trials
Not yet recruiting26 trials
Completed18 trials
Active, not recruiting17 trials
Terminated1 trial
Withdrawn1 trial
Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.6 trials
Shanxi Bethune Hospital6 trials
Janssen Research & Development, LLC5 trials
Innovent Biologics (Suzhou) Co. Ltd.4 trials
RemeGen Co., Ltd.4 trials
and 57 more

Running trials

Not yet recruiting
A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo
NCT07865312· Phase 3· Dermavon Holdings Limited· Source
Contact: Yuying Kang
Recruiting
A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT07746687· Phase 2· Janssen Research & Development, LLC· Source
Not yet recruiting
Treatment Strategy for Patients With RA-ILD
NCT07643038· Phase 4· Chinese SLE Treatment And Research Group· Source
Contact: Liyun Zhang
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Yarong Guo
Recruiting
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459· Phase 3· InSilico Medicine Hong Kong Limited· Source
Contact: Qinhan Chen
Recruiting
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
NCT07776522· Phase 2· West China Hospital· Source
Contact: Duan
Not yet recruiting
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
NCT07712094· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source
Contact: Yarong Guo
Not yet recruiting
Clinical Study on the Effectiveness of Antibiotics Combined With Bifidobacterium Quadruple Live Tablets in Treating Cirrhosis With Spontaneous Bacterial Peritonitis and Preventing Recurrence
NCT07686861· Phase 4· Peking University First Hospital· Source
Contact: Yan Wang
Recruiting
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07564596· Phase 1/2· Climb Bio, Inc.· Source
Contact: Climb Bio Investigative Site 5
Recruiting
A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis
NCT07692165· Phase 1/2· Innatus Therapeutics (Shanghai) Co., Ltd.· Source
Contact: Wang
Recruiting
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
NCT07517042· Shanghai Zhongshan Hospital· Source
Contact: Shiwei Liu, MD, PhD
Recruiting
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014· Phase 2· Eisai Co., Ltd.· Source
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986· Phase 2· Hangzhou Sumgen Biotech Co., Ltd.· Source
Contact: Liyun Zhang, Doctor
Recruiting
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
NCT07453004· Phase 2· TJ Biopharma Co., Ltd.· Source
Contact: Liyun Zhang
Recruiting
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
NCT06951646· Phase 2· Second Xiangya Hospital of Central South University· Source
Contact: Huijing Feng
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
NCT07367516· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Yarong Guo, Doctor
Not yet recruiting
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）
NCT07274137· Phase 3· MindRank AI Ltd· Source
Contact: Shiwei Liu
Recruiting
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
NCT07317934· Phase 3· Innostellar Biotherapeutics Co.,Ltd· Source
Contact: Principal Investigator
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
NCT07143045· Alpha Biopharma (Jiangsu) Co., Ltd.· Source
Contact: Junping Zhang Professor
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Yarong Guo, Doctor
Recruiting
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
NCT07323173· Phase 1· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: lei liu
Recruiting
Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)
NCT07262645· Phase 3· Danyang Huichuang Medical Equipment Co., Ltd.· Source
Contact: Xiaolei Liu, MD, PhD
Active, not recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
NCT07263776· Phase 3· Capital Medical University· Source
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065· Phase 2· Guangzhou Lupeng Pharmaceutical Company LTD.· Source
Contact: Weiwei Tian
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161· Phase 3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Contact: Liyun Zhang
Recruiting
Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management
NCT07265037· Shanxi Bethune Hospital· Source
Contact: Chen Li, Master
Active, not recruiting
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335· Phase 1· Shanghai Henlius Biotech· Source
Recruiting
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
NCT06850285· Shanxi Bethune Hospital· Source
Contact: jia wei
Recruiting
A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
NCT07099430· Phase 1/2· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: Xiangyu Ma
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study
NCT07108530· Phase 2· Shanxi Bethune Hospital· Source
Contact: Tao Wang, Dr.
Not yet recruiting
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
NCT07083739· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Shaolong He, Master
Recruiting
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07292714· Phase 2· Mabwell (Shanghai) Bioscience Co., Ltd.· Source
Contact: Yongchang Sun, Doctor
Recruiting
Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL
NCT07059156· Phase 2/3· Shanxi Bethune Hospital· Source
Contact: Tao Wang, Dr.
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Yan Wang
Active, not recruiting
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
NCT06970743· Phase 3· BeOne Medicines· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
NCT06926647· Beijing 302 Hospital· Source
Contact: Yan Wang
Recruiting
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
NCT06900920· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Shaolong He, Master
Recruiting
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Xiaochen Li, Doctor
Not yet recruiting
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06859931· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: LiYun Zhang, Doctor
Active, not recruiting
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323· Phase 2· Amgen· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297· Phase 2· Innovent Biologics (Suzhou) Co. Ltd.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06841042· Phase 1/2· Sinocelltech Ltd.· Source
Contact: Liyun Zhang
Recruiting
The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System
NCT07136025· Beijing Chao Yang Hospital· Source
Contact: Lei Wang
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Effect of Transcranial Direct Current Stimulation on Postoperative Delirium in Elderly Patients
NCT06678529· Huazhong University of Science and Technology· Source
Contact: Xiaomin zhang
Recruiting
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
NCT06760273· Shanghai Pulmonary Hospital, Shanghai, China· Source
Contact: Jin-Fu Xu

Showing 50 of 73.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lupus (SLE)8 recruiting
Childhood cancers5 recruiting
Lung cancer4 recruiting
Acute lymphoblastic leukaemia3 recruiting
Asthma3 recruiting
Gastric and oesophageal cancer3 recruiting
Melanoma3 recruiting
Multiple myeloma3 recruiting
Hepatitis B2 recruiting
Immune thrombocytopenia (ITP)2 recruiting
Liver and biliary tract cancer2 recruiting
Macular degeneration2 recruiting
Obesity2 recruiting
Acute myeloid leukaemia1 recruiting
Alzheimer disease1 recruiting
ANCA-associated vasculitis1 recruiting
Aplastic anaemia1 recruiting
Chronic lymphocytic leukaemia1 recruiting
Colorectal cancer1 recruiting
COPD1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Endometrial cancer1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
Gaucher disease1 recruiting
Gout1 recruiting
Heart failure1 recruiting
Idiopathic pulmonary fibrosis1 recruiting
Liver cirrhosis1 recruiting
Metastatic breast cancer1 recruiting
Neuroendocrine tumours1 recruiting
Rheumatoid arthritis1 recruiting
Sarcoma1 recruiting
Thyroid cancer1 recruiting
Type 2 diabetes1 recruiting
Ulcerative colitis1 recruiting
Vitiligo1 recruiting

Closed trials

Withdrawn
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT07583030· Early phase 1· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source
Completed
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229· Phase 2· Atom Therapeutics Co., Ltd· Source
Completed
A Phase Ib Study of RC1416 Injection
NCT06911866· Phase 1· Nanjing RegeneCore Biotech Co., Ltd.· Source
Completed
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06527144· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Completed
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
NCT06522997· Phase 2· Bayer· Source
Completed
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
NCT06422507· Phase 3· Bayer· Source
Completed
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
NCT06006403· Phase 1/2· Chongqing Precision Biotech Co., Ltd· Source
Completed
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
NCT05901831· Phase 3· Bayer· Source
Completed
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06091943· Phase 1· BeiGene· Source
Completed
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
NCT06093191· Phase 4· Jin-Fu Xu· Source
Completed
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT05938920· Phase 2· InSilico Medicine Hong Kong Limited· Source
Completed
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
NCT07030595· Phase 3· Alebund Pharmaceuticals· Source
Completed
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
NCT05673993· Phase 3· RemeGen Co., Ltd.· Source
Terminated
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
NCT05709093· Phase 3· TJ Biopharma Co., Ltd.· Source
Completed
Study of Telitacicept in Generalized Myasthenia Gravis
NCT05737160· Phase 3· RemeGen Co., Ltd.· Source
Completed
A Study of IBI362 in Participants With Obesity or Overweight
NCT05607680· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source
Completed
Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)
NCT05439356· Phase 3· Beijing Tiantan Hospital· Source
Completed
Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
NCT05247203· Phase 1· RemeGen Co., Ltd.· Source
Completed
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
NCT04849351· Phase 2· Hutchison Medipharma Limited· Source
Completed
Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
NCT04747496· Daiichi Sankyo· Source

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error